Dr. Kariuki will lead all finance-related and investor relations functions at the company.
Dr. Kariuki is a highly accomplished finance executive with extensive experience in healthcare strategy, life sciences investment banking, venture capital and business development.
Prior to joining VelosBio, Dr. Kariuki served as senior vice president, Corporate Development at Synthorx, Inc., where he led the company's USD 151m initial public offering, managed relationships with bankers, sell-side equity analysts and investors, and led the business development process that concluded with the successful sale of Synthorx to Sanofi for USD 2.5bn.
Prior to joining Synthorx, Dr. Kariuki was vice president at H.I.G. Capital, where he led investments into, and served on boards of, several life sciences companies.
His roles prior to H.I.G. include Senior Associate at Leerink Partners and Associate director at UBS Investment Bank.
At Leerink and UBS, Dr. Kariuki advised healthcare companies on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.
Dr. Kariuki completed a Post-Doctoral Fellowship in R and D Strategy and Analytics at Bristol-Myers Squibb and was a practicing pharmacist before transitioning to industry. He holds an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University.
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.
Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies.
The company is developing a broad pipeline of ROR1-directed therapeutics in oncologic indications with high unmet medical need. VelosBio is headquartered in San Diego.
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial